FDA clears Penumbra’s CAVT technology for DVT treatment

Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.

Penumbra's CAVT technology received FDA clearance for treating deep-vein thrombosis (DVT). The BOLT-DVT trial showed 98% of patients had successful clot removal, with immediate pain relief and improved quality of life. No serious device-related adverse events were reported. Penumbra's Lightning Flash technology aims to enhance clot removal safety and efficiency.

Boston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).

Panoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.

Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of

Penumbra (NYSE: PEN) reported THUNDER IDE study results for its THUNDERBOLT computer-assisted vacuum thrombectomy system in emergent large vessel occlusion stroke. In 216 patients, 87.5% achieved mTICI 2b-3 reperfusion, with median time-to-revascularization of 20 minutes and 2.8% device/procedure-related serious adverse events. FDA clearance and CE Mark were noted.